Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16564610 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2MEN1KMT2ALMNAPOLB | |
| SCHEMBL4128879 | 0.88 | ULK1 (0.60) | MAPK1KDRULK1JAK2JAK1 | |
| SCHEMBL4128868 | 0.88 | ULK1 (0.60) | MAPK1KDRULK1JAK2JAK1 | |
| SCHEMBL4128864 | 0.88 | ULK1 (0.60) | MAPK1KDRULK1JAK2JAK1 | |
| SCHEMBL4130879 | 0.86 | MAPK1 (0.69) | MEN1KMT2AMAPK1KDRULK1 | |
| SCHEMBL4130872 | 0.86 | MAPK1 (0.69) | MEN1KMT2AMAPK1KDRULK1 | |
| SCHEMBL4122655 | 0.86 | MAPK1 (0.69) | MEN1KMT2AMAPK1KDRULK1 | |
| SCHEMBL12907307 | 0.84 | ROCK2 (0.66) | ROCK2ROCK1MAPK1 | |
| SCHEMBL12907305 | 0.84 | ROCK2 (0.66) | ROCK2ROCK1MAPK1 | |
| SCHEMBL4134588 | 0.82 | MEN1 (0.52) | MEN1KMT2APOLBHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040701-B1 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | claimed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | SMN1; SMN2 4645/4885MEN1 4191/4885KMT2A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.